Akebia Therapeutics Inc (AKBA)
1.83
+0.01
(+0.55%)
USD |
NASDAQ |
Nov 22, 09:55
Akebia Therapeutics Total Assets (Quarterly): 207.14M for Sept. 30, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 207.14M |
June 30, 2024 | 220.20M |
March 31, 2024 | 225.48M |
December 31, 2023 | 241.70M |
September 30, 2023 | 235.00M |
June 30, 2023 | 253.71M |
March 31, 2023 | 276.86M |
December 31, 2022 | 356.05M |
September 30, 2022 | 435.89M |
June 30, 2022 | 521.80M |
March 31, 2022 | 535.36M |
December 31, 2021 | 529.35M |
September 30, 2021 | 602.27M |
June 30, 2021 | 611.86M |
March 31, 2021 | 628.70M |
December 31, 2020 | 644.14M |
September 30, 2020 | 676.14M |
June 30, 2020 | 745.17M |
March 31, 2020 | 787.72M |
December 31, 2019 | 771.20M |
September 30, 2019 | 795.22M |
June 30, 2019 | 823.53M |
Date | Value |
---|---|
March 31, 2019 | 890.79M |
December 31, 2018 | 996.54M |
September 30, 2018 | 403.83M |
June 30, 2018 | 413.78M |
March 31, 2018 | 442.71M |
December 31, 2017 | 364.25M |
September 30, 2017 | 338.59M |
June 30, 2017 | 336.82M |
March 31, 2017 | 259.26M |
December 31, 2016 | 300.22M |
September 30, 2016 | 169.12M |
June 30, 2016 | 195.64M |
March 31, 2016 | 221.44M |
December 31, 2015 | 142.94M |
September 30, 2015 | 159.59M |
June 30, 2015 | 155.66M |
March 31, 2015 | 103.46M |
December 31, 2014 | 111.00M |
September 30, 2014 | 120.17M |
June 30, 2014 | 126.36M |
March 31, 2014 | 134.03M |
December 31, 2013 | 34.66M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
207.14M
Minimum
Sep 2024
787.72M
Maximum
Mar 2020
475.29M
Average
525.58M
Median
Total Assets (Quarterly) Benchmarks
Corcept Therapeutics Inc | 784.26M |
Eli Lilly and Co | 75.61B |
Bioventus Inc | 769.49M |
NovaBay Pharmaceuticals Inc | 3.877M |
Palatin Technologies Inc | 3.415M |
Total Assets (Quarterly) Related Metrics
Total Liabilities (Quarterly) | 257.54M |
Shareholders Equity (Quarterly) | -50.40M |
Debt to Equity Ratio | -0.761 |
Current Ratio | 1.524 |
Net Debt Paydown Yield | 0.30% |